Insider · CIK 0001992260
Simrat Randhawa
Files at DNTH (Dianthus Therapeutics, Inc. /DE/). First filing Nov 14, 2025, latest Sep 3, 2026.
In brief
Simrat Randhawa files SEC Form 4 as officer at DNTH (Dianthus Therapeutics, Inc. /DE/). Since Nov 14, 2025, Simrat Randhawa has reported 0 open-market buys worth $0 and 4 open-market sells worth $15M, the latest filed on Sep 3, 2026.
A track record needs three past buys with six months of prices behind them; Simrat Randhawa has 0, so none is measured yet.
The newest scored trade: sold $2.5M of DNTH on Sep 1, 2026, filed Sep 3, 2026, scored 33 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 4 sells worth $15M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
DNTH: Dianthus Therapeutics, Inc. /DE/
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | Dianthus Therapeutics, Inc. /DE/ | $2.5M 23,124 shares | -85% | +347% from low-8% from high | |
| 25Weak | Dianthus Therapeutics, Inc. /DE/ | $2.4M 26,530 shares | -87% | +431% from low-7% from high | |
| 40Moderate | Dianthus Therapeutics, Inc. /DE/ | $2.8M 33,830 shares | -100% | +441% from low-8% from high | |
| 25Weak | Dianthus Therapeutics, Inc. /DE/ | $7.4M 196,538 shares | -215% | +139% from low-10% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 1, 2026 | DNTH DIANTHUS THERAPEUTICS INC | 23,124 0.04% of outstanding | $2.4M | Sep 1, 2026 | none |
| Jun 1, 2026 | DNTH DIANTHUS THERAPEUTICS INC | 26,530 0.05% of outstanding | $2.5M | Jun 1, 2026 | $2.8M |
| Mar 12, 2026 | DNTH DIANTHUS THERAPEUTICS INC | 33,830 0.08% of outstanding | $2.9M | Mar 12, 2026 | none |
| Nov 13, 2025 | DNTH DIANTHUS THERAPEUTICS, INC. | 196,538 0.46% of outstanding | $7.6M | Nov 13, 2025 | none |
Transactions
Every row this insider has filed, 46 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +7,500 | $17.88 | $134k | 11,500 | 40 d ago |
| Sep 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +6,249 | $21.77 | $136k | 17,749 | 40 d ago |
| Sep 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +9,375 | $22.07 | $207k | 27,124 | 40 d ago |
| Sep 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -2,600 | $105.19 | $273k | 24,524 | 40 d ago |
| Sep 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -7,215 | $106.25 | $767k | 17,309 | 40 d ago |
| Sep 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -13,309 | $106.74 | $1.4M | 4,000 | 40 d ago |
| Sep 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,500 | $0.00 | $0 | 56,776 | 40 d ago |
| Sep 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,249 | $0.00 | $0 | 41,676 | 40 d ago |
| Sep 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,375 | $0.00 | $0 | 87,500 | 40 d ago |
| Jun 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +3,998 | $8.44 | $34k | 7,998 | Jun 2, 2026 |
| Jun 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +6,908 | $17.88 | $124k | 14,906 | Jun 2, 2026 |
| Jun 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +6,249 | $21.77 | $136k | 21,155 | Jun 2, 2026 |
| Jun 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +9,375 | $22.07 | $207k | 30,530 | Jun 2, 2026 |
| Jun 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -5,428 | $89.72 | $487k | 25,102 | Jun 2, 2026 |
| Jun 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -16,943 | $90.72 | $1.5M | 8,159 | Jun 2, 2026 |
| Jun 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -4,159 | $91.37 | $380k | 4,000 | Jun 2, 2026 |
| Jun 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,998 | $0.00 | $0 | 0 | Jun 2, 2026 |
| Jun 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,908 | $0.00 | $0 | 64,276 | Jun 2, 2026 |
| Jun 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,249 | $0.00 | $0 | 47,925 | Jun 2, 2026 |
| Jun 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,375 | $0.00 | $0 | 96,875 | Jun 2, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +7,998 | $8.44 | $68k | 7,998 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +5,000 | $17.88 | $89k | 12,998 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +8,332 | $21.77 | $181k | 21,330 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +12,500 | $22.07 | $276k | 33,830 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -33,830 | $81.48 | $2.8M | 0 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,998 | $0.00 | $0 | 3,998 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 71,184 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,332 | $0.00 | $0 | 54,174 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,500 | $0.00 | $0 | 106,250 | Mar 13, 2026 |
| Feb 3, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | AGrant or award Stock Option (Right to Buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Feb 4, 2026 |
| Nov 13, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +83,978 | $8.44 | $709k | 87,978 | Nov 14, 2025 |
| Nov 13, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +3,529 | $17.88 | $63k | 91,507 | Nov 14, 2025 |
| Nov 13, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -26,166 | $35.80 | $937k | 65,341 | Nov 14, 2025 |
| Nov 13, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -42,765 | $37.04 | $1.6M | 22,576 | Nov 14, 2025 |
| Nov 13, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -18,576 | $37.72 | $701k | 4,000 | Nov 14, 2025 |
| Nov 14, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +40,287 | $17.88 | $720k | 44,287 | Nov 14, 2025 |
| Nov 14, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +37,494 | $21.77 | $816k | 81,781 | Nov 14, 2025 |
| Nov 14, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +31,250 | $22.07 | $690k | 113,031 | Nov 14, 2025 |
| Nov 14, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -109,031 | $38.14 | $4.2M | 4,000 | Nov 14, 2025 |
| Nov 13, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -83,978 | $0.00 | $0 | 11,996 | Nov 14, 2025 |
| Nov 13, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,529 | $0.00 | $0 | 116,471 | Nov 14, 2025 |
| Nov 14, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -40,287 | $0.00 | $0 | 76,184 | Nov 14, 2025 |
| Nov 14, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -37,494 | $0.00 | $0 | 62,506 | Nov 14, 2025 |
| Nov 14, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -31,250 | $0.00 | $0 | 118,750 | Nov 14, 2025 |
| Sep 23, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | AGrant or award Stock Option (Right to Buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Sep 25, 2025 |
| Feb 3, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | AGrant or award Stock Option (Right to Buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Feb 4, 2025 |
Questions about Simrat Randhawa
Answered from the filings on this page, as of the latest one.
Is Simrat Randhawa buying or selling?
In the last 12 months Simrat Randhawa reported 0 open-market buys worth $0 and 4 open-market sells worth $15M on SEC Form 4; the latest was sold $2.5M of DNTH on Sep 1, 2026. Grants, option exercises and tax withholding are not counted.
How did Simrat Randhawa's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Simrat Randhawa has 0.
Where does Simrat Randhawa file Form 4?
Simrat Randhawa has filed Form 4 at DNTH (Dianthus Therapeutics, Inc. /DE/) as EVP, Head of R&D. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.